医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

iPug, the Innovative Digital Health Platform Founded in Australia, Announces Their US Launch at the BIO International Convention 2016

2016年06月06日 AM09:45
このエントリーをはてなブックマークに追加


 

SAN FRANCISCO

iPug is a mobile friendly platform that transforms the way that research is conducted and how public health campaigns are delivered. With iPug Research Suite™, iPug recruits and engages targeted participants for high quality and real-time research results. iPug Health Suite also delivers individualized health campaigns to individuals with the right message, at the right time, on the right device with the right reward incentive, thereby moving governments away from a broadcast model of ineffective public service campaigns to a targeted reward-based communications platform. This level of engagement has proven to save time, money and has a higher success rate in influencing changed user behavior as it relates to public health.

Speaking on the emergence of digital health technology in the US and the opportunity for iPug, Steve Huff, CEO and Co-Founder of iPug, said, “It is an exciting time to be in digital health. Digital health funding is up with over $900m in investment in Q1 of this year. This represents a 50% year on year growth from the same time last year.”

After successfully launching in Australia and most notably developing the injury prevention app Cool Runnings for the Center for Children’s Burns and Trauma Research in Brisbane, iPug sees tremendous opportunity in the US to reduce public agency costs, effectively scale and deliver measurable results for public health campaigns.

At BIO, iPug will be at the Australian Pavilion from June 6-9th.

About iPug:

iPug is the world’s first mobile friendly platform that transforms the way that public research is conducted and how public health campaigns are delivered through mobile gamification.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160605005105/en/

CONTACT

iPug
Priya Ghandikota, 1 408-887-7094
press@ipug.co

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続